Companies
IRRI
Golden Rice — Provitamin A introgression.
- Country
- PH
Research
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| biofuels-bioenergy | ✓ | ✓ | ✓ | ✓ |
| crop-biotech | ✓ | ✓ | ✓ | ✓ |
Regulatorsusda-aphisepaneaefsa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Affiliation | International Rice Research Institute (IRRI) | irri.org |
| Research focus | development of provitamin A (beta-carotene) biofortified Golden Rice using transgenic methods and marker-assisted backcrossing to address vitamin A deficiency | goldenrice.org · irri.org · nature.com |
| Facility | Analytical Service Laboratory (ASL) at IRRI | openknowledge.fao.org · fao.org · nature.com |
| Grant | Funding provided by the Bill and Melinda Gates Foundation, US Agency for International Development (USAID), Rockefeller Foundation, European Commission, Swiss Federal Funding, and the Syngenta Foundation | embryo.asu.edu · pmc.ncbi.nlm.nih.gov · goldenrice.org · nature.com |
| Publications | Scientific publications including Swamy et al. (2019 & 2021), Biswas et al. (2021), and Oliva et al. (2020) regarding regulatory data, food/feed safety, and agronomic performance | goldenrice.org |
| Principal staff | Dr. B.P. Mallikarjuna Swamy (Senior Scientist/Lead Scientist for Golden Rice), Dr. Russell Reinke (Healthier Rice program lead), Jauhar Ali (Principal Scientist), and Inez Slamet-Loedin (Head of Rice Genetic Design and Validation unit) | irri.org · nature.com |
| Headcount | Approximately 1,200 to 1,831 employees (as of 2026) | openknowledge.fao.org |
Independent sources: embryo.asu.edu · fao.org · goldenrice.org · nature.com · openknowledge.fao.org · pmc.ncbi.nlm.nih.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Allelopathic crops | crop-biotech | Medium | → |
| Biofortification of crops | crop-biotech | Medium | → |
| Engineered photosynthesis and artificial chloroplasts | biofuels-bioenergy | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.